Scientists for the first time have used CRISPR gene editing to halt the progression of Duchenne muscular dystrophy (DMD) in a large mammal, according to a study by UT Southwestern that provides a strong indication that a lifesaving treatment may be in the pipeline.
The research published in Science documents unprecedented improvement in the muscle fibers of dogs with DMD – the most common fatal genetic disease in children, caused by a mutation that inhibits the production of dystrophin, a protein critical for muscle function.
Researchers used a single-cut gene-editing technique to restore dystrophin in muscle and heart tissue by up to 92 percent of normal levels. Scientists have estimated a 15 percent threshold is needed to significantly help patients.
“Children with DMD often die either because their heart loses the strength to pump, or their diaphragm becomes too weak to breathe,” said Dr. Eric Olson, Director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine. “This encouraging level of dystrophin expression would hopefully prevent that from happening.”
DMD, which affects one in 5,000 boys, leads to muscle and heart failure, and premature death by the early 30s. Patients are forced into wheelchairs as their muscles degenerate and eventually onto respirators as their diaphragms weaken. No effective treatment exists, though scientists have known for decades that a defect in the dystrophingene causes the condition.
The Science study establishes the proof-of-concept for single-cut gene editing in dystrophic muscle and represents a major step toward a clinical trial. Already Dr. Olson’s team has corrected DMD mutations in mice and human cells by making single cuts at strategic points of the mutated DNA.
The latest research applied the same technique in four dogs that shared the type of mutation most commonly seen in DMD patients. Scientists used a harmless virus called adeno-associated virus (AAV) to deliver CRISPR gene-editing components to exon 51, one of the 79 exons that comprise the dystrophin gene.
CRISPR edited the exon, and within several weeks the missing protein was restored in muscle tissue throughout the body, including 92 percent correction in the heart and 58 percent in the diaphragm, the main muscle needed for breathing.
“Our strategy is different from other therapeutic approaches for DMD because it edits the mutation that causes the disease and restores normal expression of the repaired dystrophin,” said Dr. Leonela Amoasii, lead author of the study and Assistant Instructor of Molecular Biology in Dr. Olson’s lab. “But we have more to do before we can use this clinically.”
The lab will next conduct longer-term studies to measure whether the dystrophin levels remain stable and to ensure the gene edits do not have adverse side effects.
Dr. Olson hopes the next step beyond dogs is a clinical trial, which would be among several that UT Southwestern’s gene therapy center aims to launch in the coming years to address numerous deadly childhood diseases.
In the meantime, Dr. Olson’s recent work has spawned a biotechnology company, Exonics Therapeutics Inc., which is working to further optimize and bring this technology to the clinic. Exonics intends to extend the approach to additional DMD mutations, as well as other neuromuscular diseases. Exonics has licensed the technology from UT Southwestern.
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Launceston's Jesse Ansell, who lives with muscular dystrophy, is grateful for the Make A Wish Foundationon November 27, 2020 at 1:30 pm
It was a dream come true for the 14-year-old, who lives with duchenne muscular dystrophy - a severe inherited disorder of progressive muscular weakness, typical in boys. Jesse was diagnosed with the ...
- Duchenne Muscular Dystrophy Market 2020: To Witness Increase In Revenues By 2027 | FibroGen F. Hoffmann-La Roche Ltd, ITALFARMACO S.p.A., BioMarinon November 24, 2020 at 4:50 am
Global duchenne muscular dystrophy market is expected to gain market growth in the forecast period of 2020 to 2027 Data Bridge Market Research analyses the market is growing at a healthy CAGR in the ...
- Youth inspires ND Highway Patrol in fundraising for Duchenneon November 20, 2020 at 10:43 pm
An 11-year-old boy fighting a brave battle with a rare form of muscular dystrophy is giving the North Dakota Highway Patrol inspiration in its latest fundraiser. When considering a cause for their ...
- Lilly to Partner on Research for Duchenne Muscular Dystrophyon November 20, 2020 at 2:53 pm
Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Precision Biosciences Inc. (Nasdaq: DTIL), a biotech company based in Durham, North Carolina, are partnering on a potential treatment for Duchenne ...
- Lilly, Precision Biosciences team up on Duchenne gene therapy in $135M dealon November 20, 2020 at 6:47 am
Once wary of inking deals around gene therapy, Eli Lilly is jumping headfirst into developing treatments that edit genes within the body. It’s teaming up with cell and gene therapy biotech Precision ...
- N.J. charities can’t sell raffle tickets online. Now, one non-profit is pushing back.on November 19, 2020 at 12:26 pm
The West Long Branch non-profit, Jars of Hope, says a raffle they were holding was shut down by the Attorney General's Office.
- A mum becomes standard bearer for young Duchenne suffererson November 19, 2020 at 5:05 am
Elizabeth Vroom decided to devote her life to her son, who has Duchenne muscular dystrophy, and she took it so far that she has become the president of the World Duchenne Organization, the ...
- Manalapan charity wants to raffle a Ford Mustang online; NJ says noon November 19, 2020 at 3:27 am
Rep. Chris Smith asked Gov. Murphy for a waiver for JAR of Hope and other nonprofits, many of which are struggling to raise money during the pandemic.
- Swarnajayanti Fellow may provide new genetic treatment for thalassemia, Duchenne muscular dystrophy, haemophiliaon November 18, 2020 at 8:19 pm
Kolkata, Nov 19 (UNI) Duchenne Muscular Dystrophy, a severe type of muscle weakness that usually begins at an early age and worsens quickly, may soon have a new strategy of treatment through genetic ...
- ReveraGen Receives $3.3 Million NIH Commercialization Readiness Pilot Grant for NDA Preparations for Vamorolone in Duchenne Muscular Dystrophyon November 17, 2020 at 9:52 am
Funds will support NDA preparatory activities for anticipated filing in 2021 --, 08:30 AM Eastern TimeRockville, Maryland—ReveraGen, Inc., a privately held company developing vamorolone (VBP15) as a p ...
via Bing News